Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

PAH

- PMLiVE

Afinitor and Uptravi gain funding from NHS England

Rare disease treatments navigate tricky market access route

- PMLiVE

J&J’s Jane Griffiths named global head of Actelion

Appointment will effect once Swiss biotech's acquisition is completed

Actelion HQ Switzerland

EU nod for Actelion’s skin cancer drug Ledaga

Still need to meet CHMP post-approval requirements

Actelion HQ Switzerland

J&J agrees $30bn deal to acquire Actelion

Swiss biotech to retain control of early-stage pipeline as J&J takes minority stake in R&D spin-out

Actelion HQ Switzerland

Actelion reports late-stage trial failure as J&J talks continue

MAESTRO trial results disappointing but unlikely to lead to a breakdown in talks

- PMLiVE

J&J back in frame to buy Actelion after Sanofi talks break down

Parties now in exclusive negotiations about a possible deal

Deal Watch November 2016

Actelion, Allergan, Johnson & Johnson, Novartis and more feature in this month's pharma deals round-up

Actelion HQ Switzerland

J&J abandons talks with Actelion as another suitor circles

Biotech said to be holding out for a higher offer as speculation of Sanofi interest builds

Actelion HQ Switzerland

Resurgent Actelion catches J&J’s eye

Confirms talks of possible take over after Uptravi sees ‘outstanding’ sales

Actelion HQ Switzerland

Actelion gets EU go-ahead for Uptravi in PAH

Oral therapy predicted to become $1bn-plus product

EU flag

CHMP backs orphan drugs Uptravi and Coagadex

EMA advisors set Actelion and Bio Products therapies on path to European approval

Actelion HQ Switzerland

Actelion claims first approval for PAH therapy Uptravi

Gains US approval from the FDA for its key pipeline drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links